Albany Molecular Research Overview
Albany Molecular Research (AMRI) has a P/E ratio of -13.18, below the sector sector average of 35.6.
Get informed when a big investor buys or sells
+ Follow-13.18
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Albany Molecular Research (AMRI) currently reports a P/E ratio of -13.18. That is below the sector sector average of 35.6. Use the charts on this page to explore Albany Molecular Research's P/E ratio history and peer comparisons.
Albany Molecular Research's P/E ratio of -13.18 is lower than the its sector sector average of 35.6. That is roughly 137.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Albany Molecular Research's market price to a fundamental measure such as earnings, sales, or book value. At -13.18, AMRI can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -13.18, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 35.6. From there, open related valuation or income-statement pages for Albany Molecular Research, and consider following AMRI for alerts when major investors trade the stock.
